Li Yingyun believes that, when viewed from the perspective of serving patients, different products have distinct positioning and different payers. “In the field of oncology, digital health cannot replace pharmaceuticals; it plays a more supportive role. We have been continuously exploring how to collaborate with supportive care providers to deliver better care to more patients.” By delving deeply and thoroughly into this process, all stakeholders—patients, physicians, and hospital departments—stand to benefit: patients receive higher-quality medical services, while the workload and costs for physicians and departments are reduced, thereby also creating value for enterprises and product developers.

I. Domestic News

1. MicroSight Medical’s AI Product for Digestive Endoscopy Gains FDA and CE MDR Approval, Market Launch Underway

In November 2021, EndoScreener (an AI-assisted diagnostic software for digestive endoscopy), the flagship product developed by Wision A.I., successively obtained CE MDR certification and FDA clearance, gaining near-simultaneous approval to enter the European and U.S. markets.It is reported that Wision A.I.’s colonoscopy-assisted diagnostic software has obtained the first Class II registration certificate among similar products since the mandatory implementation of the European Union’s new Medical Device Regulation (MDR), and it is currently the only standalone Software as a Medical Device (SaMD) in this category.

Two weeks after obtaining CE-MDR certification, Wision A.I. secured FDA approval, becoming the first medical AI product approved by the FDA based on clinical evidence from U.S.-based randomized controlled trials. The clearance of EndoScreener for market entry by both the EU CE and the U.S. FDA signifies that a methodological framework for real-time dynamic video-based medical AI applications has been established in the field of international medical device regulation.

2. A Powerhouse Partnership! Shukang Collaborates with Sanofi: Digital Therapeutics for Lipid Management in Patients with Atherosclerosis

Recently, Shukang was invited to participate in the Sanofi Innovation Summit themed “Dream and Go.” The summit focused on cutting-edge topics such as “digital therapeutics” and “early disease screening and prevention.” Hosted by the renowned pharmaceutical company Sanofi, the event brought together medical experts, leaders, practitioners, and investment institutions from both China and abroad. At the event, Ren Songqing, COO of Shukang, presented the “Shukang Comprehensive Rehabilitation System” as a case study, introducing how the Shukang App, as a digital therapeutic approved by the National Medical Products Administration (NMPA), has implemented the concept of digital therapeutics in practice. It provides doctors and patients with a scientific and efficient chronic disease rehabilitation management model through “lifestyle interventions.” Shukang has partnered with Sanofi, a globally leading pharmaceutical company, to customize digital therapeutics for lipid management in patients with atherosclerotic cardiovascular disease (ASCVD). By combining lifestyle interventions with pharmacological treatments, the collaboration aims to explore solutions for lipid management in ASCVD patients and evaluate improvements in their quality of life and health outcomes.

3. Weimai Makes Debut at Sanofi Innovation Summit, Building an Innovative Digital Therapeutics Service Platform

At the conference, Hu Wei, Chief Medical Officer of Weimai, introduced the company’s innovative progress in fields such as “Internet Plus Full-Course Disease Management” and digital therapeutics. He stated that “technology illuminating medicine” has been Weimai’s consistent philosophy. Guided by this principle, Weimai has developed into a leading “Internet Plus Full-Course Disease Management” service platform in China. As one of the first companies in China to receive certification from the Digital Therapeutics Alliance (DTA), Weimai leverages the theoretical framework of “(EMR + RWD)/Neumann AI + Evidence-Based Medicine = DTx” to provide patients with software-driven, evidence-based full-course disease management and full-lifecycle health services. Seizing the opportunity presented by Sanofi’s innovation ecosystem, Weimai will connect high-quality resources and strengthen collaboration with industry leaders, including Sanofi, to jointly build a new ecosystem for full-course disease management and digital therapeutics.

4. Alibaba Health’s Financial Report Reveals Key Progress, Internet Healthcare Finds Another Breakthrough

On November 24, Alibaba Health (00241.HK) released its interim results announcement for fiscal year 2022, disclosing data related to chronic disease patients for the first time. The “Chronic Disease Welfare Program” under its self-operated business provides users with a series of services, including discounted high-quality medications, dedicated physicians, medication follow-ups, and patient education. The number of chronic disease users reached 5 million, representing a year-on-year increase of 170%. In addition, through platforms such as Tmall Medical Health, the Yilu App, and Xiaolu Traditional Chinese Medicine, Alibaba Health continues to provide various services to a broader population of chronic disease patients.While solidifying its reach in both B2B and B2C segments, Alibaba Health has continued to ramp up its investments in digital healthcare. During the reporting period, Alibaba Health successively established partnerships with a range of companies, including ZhongAn Insurance, Huirui Gene, Roche, Haisco Pharmaceutical, and AstraZeneca, further strengthening its closed-loop ecosystem integrating “healthcare, pharmaceuticals, and insurance.”

Behind this strategic layout, we can see Alibaba Health making significant strides in both the e-commerce ecosystem and healthcare services. However, a deeper examination of its logic—partnering with Xiao Lu TCM, making strategic investments in LinkDoc, collaborating with ZhongAn Insurance, and engaging with top 100 pharmaceutical companies—reveals that an “Internet + Chronic Disease Management” business line has been quietly established.

5、Hunan Establishes “Center for Brain Science and Artificial Intelligence” to Further Explore Digital Psychotherapy

Recently, Xiangya Hospital of Central South University officially launched the “Center for Brain Science and Artificial Intelligence.” By integrating these two disciplines, the Center aims to explore five major digital mental health modules: digital diagnosis and assessment for patients with psychiatric and psychological disorders, digital psychotherapy, digital psychological rehabilitation, digital psychological prevention for the general public, and a system for cognitive enhancement and brain intelligence development. Upon its establishment, the Center will focus on common psychiatric and psychological conditions such as depression, obsessive-compulsive disorder (OCD), internet gaming disorder, sleep disorders, social anxiety disorder, learning disabilities, and attention-deficit/hyperactivity disorder (ADHD), further advancing research into digital psychotherapies. For instance, it will prioritize the development of a precision digital psychological prevention system for the public, actively exploring how technological means can be used to precisely prevent conditions such as internet and gaming addiction, while also conducting pioneering research on improving brain efficiency and unlocking the intellectual potential of the human brain.

6. Wangli Technology’s Research on Digital Therapeutics for Addiction Presented at the National Symposium on Drug Abuse Prevention and Control, Earning High Acclaim from Industry Luminaries

Recently, Wangli Technology was invited to attend the 2021 National Symposium on Drug Abuse Prevention and Control and the 20th Academic Conference of the China Association for Drug Abuse Prevention and Control. The theme of the conference was “Application of Digital Therapeutics and AI Algorithms in the Diagnosis and Treatment of Addiction.”

Professor Hao Wei, from the Second Xiangya Hospital of Central South University and Director of the WHO Collaborating Centre for Research and Training in Psychosocial Factors, Addictive Behaviours and Health, and President Li Yi of the Wuhan Mental Health Center provided professional guidance during the conference preparations and presided over the meeting. Wangli Technology presented its research findings on objective assessment and online intervention therapies in the field of addiction, highlighting that digital therapeutics enhance treatment accessibility. President Li noted that digital therapeutics represent a significant expansion of the field with substantial potential; mobile applications offer advantages such as accessibility and anonymity, unrestricted by time or space. He expressed hope that Wangli Technology would strive to develop more clinically actionable and highly practical products that benefit patients.

7. Wang Qiangyu, Founder of Yisheng Jiankang: Precision Micro-Testing Drives Digital Health Management

On November 20, the 5th SATOL 2021 World Life Science Conference, themed “Exploration, Integration, and Innovation,” concluded successfully in Liangzhu, Hangzhou. During the conference, at the Digital Healthcare and Internet Summit—co-organized by Zhejiang Institute of Digital Medical and Health Technology and Shulan Internet Hospital (Hangzhou) Co., Ltd.—the founder and CEO of Yisheng Jiankang (Hangzhou) Life Technology Co., Ltd. delivered a keynote speech titled “The Significance of Precision Micro-testing for Human Health Monitoring,” discussing the practice and application of micro-testing and digital therapeutics in women’s health management. Yisheng Jiankang is a high-tech enterprise committed to the mission of “providing lifelong testing and health management services to the public,” with a strategic focus on the internet healthcare sector. He stated that health management is a product aligned with socioeconomic and era-specific developments, while precision micro-testing serves as the key to unlocking this domain. Essentially, Yisheng Jiankang aims to leverage internet-based approaches to make precision medical testing online, accessible to the general public, and routine.

8. PokCity Signs Strategic Cooperation Agreement with Yangzhi Rehabilitation Hospital Affiliated to Tongji University to Explore Gamified Digital Therapeutics

Pok City Digital Therapeutics Strategy Launch Conference and Signing Ceremony for the Strategic Cooperation on Digital Therapeutics between Pok City and Yangzhi Rehabilitation Hospital Affiliated to Tongji University Held in ShanghaiJin Lingjing, President of Yangzhi Rehabilitation Hospital Affiliated to Tongji University, and Li Jing, Co-founder and CTO of Pok City, signed the strategic cooperation agreement on behalf of both parties. Leveraging Pok City’s advanced game development concepts and technologies, and combining them with the clinical medicine and scientific research strengths of Yangzhi Rehabilitation Hospital Affiliated to Tongji University, the two parties will establish in-depth cooperation in areas such as “game-based diagnosis, game-based treatment, game-assisted patient care, and game-supported medical practice,” jointly exploring gamified digital therapeutics.

Li Jing introduced the gamified digital therapeutics project previously undertaken by both parties, titled “Customized Linked Memory Game.” This project primarily targets individuals with mild cognitive impairment (MCI), reshaping traditional training programs through gamification to enhance adherence. It aims to improve various cognitive functions across multiple dimensions and to slow down and delay the progression from MCI to dementia. The project is currently in the clinical trial phase.

II. Overseas News:

1. How Whoop, the Most Valued Health Monitoring Device Startup in the U.S., Captures Users' Minds

Founded in 2012 and headquartered in Boston, Whoop specializes in the research, development, and design of health tracking and sports wearable devices. Its flagship product is the screen-free Whoop Strap, a smart fitness band that leverages proprietary 24/7 monitoring and analytics to help users optimize their training, recovery, and sleep quality. In addition to offering hardware in various models and colors, Whoop has launched an app focused on health education, which provides personalized recommendations for adjusting sleep and training habits based on data collected from the wristband. Whoop’s patented algorithms measure and analyze metrics such as blood pressure and heart rate to provide insights into users’ cardiopulmonary health. The device also features a sleep coach with haptic alerts, using vibrations to wake users according to their individual needs and sleep cycles. In March 2020, Whoop added COVID-19 monitoring capabilities to its product suite; by tracking users’ daily respiratory rates, the system issues alerts when anomalies are detected. Recognized by professional athletes for the reliability of its collection, processing, and analysis of exercise physiology data, Whoop has helped many members improve their bodily awareness, sleep quality, behavioral habits, training efficiency, alcohol consumption patterns, and dietary regularity.

2、The First-Ever “Game Prescription Drug” Approved by the FDA! About Half an Hour a Day Can Alleviate ADHD in Children 

Recently, the U.S. Food and Drug Administration (FDA) approved EndeavorRx, the first-ever video game for medical use.According to reports, this special “prescription drug” will be used to treat children aged 8 to 12 years with attention-deficit/hyperactivity disorder (ADHD, hereinafter referred to as “hyperactivity disorder”).

The aforementioned Akili executive stated that they have conducted clinical studies on multiple indications, including ADHD, and demonstrated that this technology shows promise in improving certain cognitive functions in children.Through scientifically grounded design, EndeavorRx is powered by adaptive algorithms that assess a child’s performance every second of gameplay to adjust difficulty levels accordingly, thereby delivering a personalized therapeutic experience for each pediatric patient with ADHD. Research findings indicate that upon completion of this game-based therapy, children demonstrate improvements in attention, academic performance, and other assessment metrics.

However, the paper indicates that EndeavorRX has currently demonstrated efficacy only for attention deficits in attention-deficit/hyperactivity disorder (ADHD), with no significant effect on other ADHD symptoms such as hyperactivity. Therefore, these findings are insufficient to support replacing current pharmacological treatments for ADHD with EndeavorRX.

3、How Strong Is the R&D Company’s Technological Reserve for Its VR Therapy for Chronic Pain, Which Has Received FDA Clearance?

Recently, the U.S. Food and Drug Administration (FDA) announced that “EaseVRx,” a prescription therapy using virtual reality (VR) to treat chronic back pain, has received clearance and has been officially added to the FDA’s list of digital therapeutics. EaseVRx was developed by AppliedVR, a company dedicated to providing VR-based therapeutic solutions to address the complexities of chronic pain. Grounded in cognitive behavioral therapy and mindfulness, AppliedVR’s EaseVRx is the first VR-based prescription therapy to receive the FDA’s Breakthrough Device designation. EaseVRx offers a comprehensive approach that addresses the biological, psychological, and social factors influencing how individuals experience chronic pain, enabling patients to change their pain management strategies, cultivate new positive habits and coping skills, and thereby improve their quality of life. A unified analysis and summary of the company’s entire patent portfolio reveal that AppliedVR’s current patent layout primarily focuses on specialized technical areas such as respiratory monitoring, headsets, audio data, and device identification.

III. Policy Trends

Announcement of the National Medical Products Administration on Issuing Two Registration Review Guidelines, Including Requirements for Submission of Clinical Trial Data for Medical Devices (No. 91 of 2021)

To strengthen the supervision and guidance of medical device product registration and further improve the quality of registration review, the National Medical Products Administration has organized the formulation of the “Guiding Principles for Registration Review of Clinical Trial Data Submission for Medical Devices” and the “Guiding Principles for Registration Review of Clinical Trial Data Submission for In Vitro Diagnostic Reagents.”

Clinical trial data for medical devices constitute one of the key supporting materials for evaluating the safety and effectiveness of medical devices. The standardized collection, organization, analysis, and submission of such data help improve the quality of clinical trial implementation and management, while also enabling regulatory authorities to rapidly and efficiently monitor trial progress, thereby enhancing review efficiency.

Clinical trial data for in vitro diagnostic reagents constitute one of the key supporting materials for evaluating product safety and effectiveness. Standardized collection, organization, analysis, and submission of clinical trial data help improve the quality of clinical trial implementation and management, while also enabling regulatory authorities to quickly and efficiently monitor the progress of clinical trials, thereby enhancing review efficiency.

IV. Investment and Financing Updates

1. ieso Raises $53 Million, Aiming to Address the Global Mental Health Crisis Through Digital Therapeutics

ieso, a leader in the UK’s digital mental health sector, recently announced the completion of a $53 million Series B financing round led by the investment firm Morningside. Sony Innovation Fund and existing shareholders IP Group, Molten Ventures, and Ananda Impact Ventures also provided additional new investment.

The funds raised will help ieso address the global mental health crisis by developing autonomous treatment systems that match the high standards of human care services, thereby significantly reducing healthcare system costs.

IESO’s AI-powered digital assessment tools and treatments for mental health conditions will be built on insights derived from the world’s largest dataset of outcome-linked therapy records, which has accumulated over 460,000 hours. These data encompass insights into and treatments for common mental health conditions, including depression and anxiety, as well as conditions associated with chronic diseases such as diabetes.

2. Deepening Expertise in Mental Health: Tsinghua University Spin-off “Lingxin Intelligence” Completes Angel Round Financing

On November 22, Beijing Lingxin Intelligent Technology Co., Ltd., a startup incubated by the Department of Computer Science and Technology at Tsinghua University, announced the completion of its angel financing round, which was exclusively invested by Tsinghua University alumni. Lingxin Intelligence was founded by Professor Huang Minlie from Tsinghua University, and its founding team members come from prestigious universities and research institutions such as Tsinghua University, Peking University, and Beijing Normal University. Since its establishment, Lingxin Intelligence has been committed to applying the most advanced artificial intelligence technologies to digital diagnostic and therapeutic services for mental health. By establishing an advanced AI-based digital therapeutics system, the company provides high-quality, low-cost, personalized, and round-the-clock emotional support, psychological counseling, and intervention solutions for clinical patients and the broader population with suboptimal mental well-being, thereby delivering more scientific and efficient mental health services to users.

Currently, the company’s most advanced project is AM-D01, a therapeutic intervention for persistent depressive disorder (PDD) based on a self-developed AI-integrated cognitive behavioral therapy (CBT) system. The project is currently conducting a series of clinical trials and studies across diverse populations. Commenting on the successful closure of this funding round, Professor Huang Minlie, founder of Lingxin Intelligence, stated that mental health remains the core issue they are addressing. Looking ahead, Lingxin Intelligence will continue to deepen its expertise in the mental health sector, providing patients with more effective treatment options that offer higher adherence rates.

3. Gaming to Improve Cognitive Function: Digital Therapeutics Startup Secures $160 Million in Funding

Akili Interactive is a research and development company that is developing clinically proven video games to improve cognitive function. The company’s flagship prescription video game, EndeavorRx, has received U.S. FDA approval for marketing as a treatment for attention-deficit/hyperactivity disorder (ADHD). Akili stated that it will continue to push the boundaries of traditional medicine by providing digital therapeutics to patients.

In 2021, Akili announced the completion of $160 million in financing, including a $110 million Series D round. Akili will use the new funds to help commercialize its EndeavorRx, while also developing other video game-based treatments for acute and chronic cognitive impairments. EndeavorRx requires children to navigate an animated character of their choice along a path filled with obstacles, avoiding hazardous areas while collecting targets. As they complete each level, players can unlock new levels and characters and build their virtual world. Throughout the gameplay, Akili’s platform uses proprietary algorithms to continuously adapt to the player’s needs and abilities, thereby providing fully personalized treatment for each patient.

4、Focused on Clinical Data Analytics, Saama Raises Up to $430 Million in Funding

Saama Technologies, founded in 1997, is an AI-driven intelligent clinical data analytics platform. Saama enhances services for the life sciences industry through data. Its AI-powered clinical data analytics platform, LSAC, employs novel machine learning algorithms to deliver real-time, clear clinical data and facilitate the discovery of new therapies by integrating data from multiple sources. LSAC provides a unified approach to clinical trial data management and analysis. Its pre-trained, AI-embedded intelligent applications can learn complex patterns within clinical data and provide predictive insights to accelerate clinical research processes across multiple therapeutic areas and domains.

In 2021, Saama announced that it had secured up to $430 million in funding. The company intends to use these funds to accelerate its strategic initiatives, including expanding its commercialization capabilities and further investing in artificial intelligence research and development.

▶ Recommended Industry-Related Reports ◀

1. "Shaping the Future of Health Data: 10 Major Scenarios"

The global healthcare industry faces a unique challenge: creating a health data ecosystem that serves both the needs of citizens and patients, as well as the demands of the industry and innovation. Currently, data is scattered across isolated silos or trapped within proprietary systems and platforms. Consequently, when it comes to health data, the lack of interoperability, collaboration, and consensus hinders our ability to meet patient needs and impedes the realization of a future healthcare system that is patient-centered and value-based. This need is particularly acute in Europe, where chronic diseases and an aging population are driving up healthcare costs against a backdrop of data fragmentation and a complex regulatory environment. To explore new pathways for resolving the challenges of the health data ecosystem, this research report, developed with the enthusiastic participation and support of more than 50 experts, outlines a future blueprint through ten key scenarios, guiding the healthcare industry toward a promising future for health data. The report also includes profound insights from various partners within the ecosystem, sharing their perspectives on the future of health data.

2、“Digital Therapeutics: Future Digital Health Tools and Virtual Care”

Digital therapeutics are poised to make significant strides in the coming years, yet regulatory and reimbursement barriers remain in practical application. Furthermore, these interventions face critical challenges related to valuation, revenue generation, and marketing. Digital therapeutics are still seeking optimal product-market fit—specifically, identifying which conditions are best suited for digital therapeutic solutions and can deliver the greatest value through cost savings. Companies in this sector must also determine the most effective business models and pricing strategies.

The main contents of the report are as follows:●Overview ●Background and Three Key Principles to Keep in Mind ●The Relevance of Digital Therapeutics Amid the COVID-19 Pandemic ●Market Outlook ●Opportunities and Benefits for Stakeholders ●Challenges ●Summary

1. The Future of Digital Therapeutics — Zhiyin Capital

In 2020, a McKinsey research report pointed out that investment in the Digital Therapeutics (DTx) market had grown continuously at an average annual rate of over 40% for nearly the past decade. In November 2020, China’s National Medical Products Administration (NMPA) approved the first digital therapeutic product, marking the launch of a new track for digital therapeutics in China. Consequently, 2021 is widely recognized by the industry as the inaugural year of digital therapeutics.

Given that the adoption of digital therapeutics (DTx) and industry development are still in their early stages, DTx companies are exploring various business models, each with its own advantages and challenges. From an industry-wide perspective, DTx represents a novel therapeutic approach with the potential to drive genuine clinical outcomes, optimize treatment protocols, and reduce healthcare institutions’ costs. Large pharmaceutical companies are also placing significant emphasis on digital initiatives, advancing implementation through internal development, external investments, or partnerships. We firmly believe that China’s DTx market will experience rapid growth in the future, commensurate with China’s share of one-sixth of the global digital economy.

2、The Rise of the Hundred-Billion-Dollar Digital Healthcare Era: Business Models Poised for Breakthroughs as Sino-Foreign Collaboration Emerges as a Trend

Currently, there are still many pain points in the construction of domestic information systems that urgently need to be addressed.

In an interview, Yang Gang, Associate Chief Physician at Jiangsu Province People’s Hospital, stated that digital therapeutics should focus on three key aspects: first, quantifying previously subjective patient perceptions; second, establishing more comprehensive industry standards and processes; and third, concentrating on the software itself and delivering personalized patient services.

“Leveraging big data, knowledge graphs, and artificial intelligence, digital therapeutics can perform patient clustering or develop individualized patient profiles, thereby establishing personalized standard care pathways. On this basis, digital therapeutics must ultimately be grounded in rigorous evidence-based medicine to demonstrate their efficacy, which represents the viable path forward for the field.” From the perspective of current development trajectories, talent, capital, and foundational research are the three critical factors driving independent innovation. Furthermore, engaging in multi-faceted collaboration and resource sharing with multinational corporations will become the mainstream trend for Chinese enterprises in the future.

3、What Is Not “Digital Therapeutics”? — A Medical Student’s Perspective on Healthcare

As a medical-grade digital therapeutic, it must obtain approval from medical device regulatory authorities before entering clinical application, whether prescribed to patients or used over-the-counter (OTC) for self-care. The most critical question is whether the product qualifies as a “medical device.” If not, it does not fall under the category of “digital therapeutics.” According to international medical device regulations, medical devices require registration and certification and must comply with Risk Class I or IIa requirements. China’s regulatory framework imposes similar mandates. Many highly practical software applications or apps serve merely for document management or communication; others repackage healthcare services into digital formats for easier access, or incorporate general wellness tips or guidance. However, these products lack evidence-based or clinically validated proof of diagnostic or therapeutic benefit for diseases. Such software products are not “digital therapeutics.”

4、The Path to Commercial Monetization for Digital Therapeutics: The Golden Key to Unlocking the Healthcare and Wellness Market

Currently, given that the adoption and industry development of digital therapeutics are still in their early stages, digital therapeutics companies are exploring various models, each with its own advantages and challenges.

From an industry-wide perspective, digital therapeutics represent a novel treatment modality with the potential to drive genuine therapeutic outcomes, optimize treatment protocols, and reduce costs for healthcare institutions.Large pharmaceutical companies also place significant emphasis on digitalization initiatives, advancing their implementation through in-house development, external investment, or partnerships.

Therefore, collaboration between digital therapeutics (DTx) companies and pharmaceutical firms represents a critical early-stage model, as it not only integrates DTx research and development with industry insights but also leverages pharmaceutical companies’ marketing channels to rapidly establish sales distribution.

Unlike the model abroad that relies on commercial health insurance for payment, the payment models implemented in China are a bottleneck constraining the development of the entire industry.Currently, out-of-pocket payments remain the primary reimbursement source for digital therapeutics (DTx) in China. To secure inclusion in government medical insurance and commercial insurance coverage, DTx must continuously expand its therapeutic scope and depth while raising societal awareness. The future of digital therapeutics is poised to be brighter.

Disclaimer: The information provided on this account is for general reference only, is not directed at any specific individual or team, and does not represent the views of this account.

The Workplace Is Like Sailing a Ship

Riding the right trend enables you to quickly take the helm

Only by keeping pace with cognitive advancements can you be driven to move forward continuously.

In the Past, Thanking My Persistent “Self”

To the Future: Gratitude to My "Self" for Constantly Striving for Excellence

Digital Therapeutics Frontier Report Bundle: Seize the Industry’s Critical Window!

Participation Methods: (Choose One)

1. Follow the official account and reply with “Welfare Collection”, share your personalized poster and invite two friends to support you. Upon completion, you will receive a premium package of frontier reports on digital therapeutics.

2. Fill in the “Survey Questionnaire”, take a screenshot for your records, and add the staff member “VCBeat dtx” to claim your gift package. (Click the red text to fill in)

(Staff: VCBeat dtx)